Document Detail

Oral phosphodiesterase-5 inhibitors and sperm functions.
MedLine Citation:
PMID:  18596704     Owner:  NLM     Status:  MEDLINE    
This review aims to elucidate the possible effects of phosphodiesterase-5 (PDE5) inhibitors on sperm functions. PDEs hydrolyze cyclic nucleotides, and together with adenylyl and guanylyl cyclase, which catalyze the formation of cAMP and cGMP, regulate the levels of these second messengers in cells. cGMP-specific PDE5 is one of the PDEs that have been intensively studied because of its fundamental pharmacological relevance, as oral PDE5 inhibitors are used successfully in treating erectile dysfunction. In addition, they have shown diverse beneficial actions in different disease categories. Specific relevance of the cGMP system in reproductive functions has been recently proposed. Its use was shown to be devoid of effects on semen volume, concentration, sperm membrane integrity or sperm penetration assay. Most available studies demonstrated a significant increase in sperm motility and viability both in vivo and in vitro, which seems to be enhanced at low doses and reduced at high concentrations. Also, these molecules showed a role in capacitation and a debated one concerning acrosome reaction. However, due to the relative short period since the launching of oral PDE5 inhibitors, more investigations should be carried out in wider scales to assess their effect(s) on variant sperm function that could be beneficial as potential therapeutic approaches.
T Mostafa
Related Documents :
17455234 - Camkii can participate in but is not sufficient for the establishment of the membrane b...
9473324 - The calcium transient in sea urchin eggs during fertilization requires the production o...
8948594 - The cyclic gmp-mediated calcium release pathway in sea urchin eggs is not required for ...
16894544 - The histamine h1 receptor activates the nitric oxide pathway at fertilization.
10856124 - Activation of volume-regulated cl(-) channels by ach and atp in xenopus follicles.
2893234 - Inhibition of cardiac na+, k+-atpase activity by dynorphin-a and ethylketocyclazocine.
Publication Detail:
Type:  Journal Article; Review     Date:  2008-07-03
Journal Detail:
Title:  International journal of impotence research     Volume:  20     ISSN:  1476-5489     ISO Abbreviation:  Int. J. Impot. Res.     Publication Date:    2008 Nov-Dec
Date Detail:
Created Date:  2008-11-10     Completed Date:  2009-03-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007383     Medline TA:  Int J Impot Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  530-6     Citation Subset:  IM    
Department of Andrology & Sexology, Faculty of Medicine, Cairo University, Cairo, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Membrane / drug effects
Cyclic Nucleotide Phosphodiesterases, Type 5 / antagonists & inhibitors*,  metabolism
Phosphodiesterase Inhibitors / administration & dosage*
Sperm Motility / drug effects
Spermatozoa / cytology,  drug effects*,  enzymology*
Reg. No./Substance:
0/Phosphodiesterase Inhibitors; EC Nucleotide Phosphodiesterases, Type 5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Improvements in sexual quality of life after moderate weight loss.
Next Document:  Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome.